 Recently, the results of the phase III PERSIST-1 trial comparing pacritinib to best available therapy BAT in patients with MF was reported at the 2015 American Society of Clinical Oncology ASCO annual meeting. Pacritinib was found to be significantly more effective than BAT at reducing spleen volume at 24 weeks of therapy and improving constitutional symptoms. 